BSBE(SZ:300406) Quan Jing Wang·2025-11-06 07:07Group 1 - The sixth Panoramic Investor Relations Gold Award was recently announced, with Jiukang Biological (300406.SZ) winning the "Outstanding IR Team" award and its Secretary Wang Jianmin receiving the "Outstanding Secretary" award [1] - The evaluation process involved self-nomination, public online voting, professional index scoring, and expert review, covering thousands of A-share companies, establishing itself as a benchmark in the capital market IR field [1] - The award focuses on six innovative dimensions: digital investor relations, response to small investors' concerns, institutional attention, market value management, shareholder returns, and ESG value dissemination, marking Jiukang Biological's IR management as recognized by the capital market [1] Group 2 - Jiukang Biological has been a leader in the domestic in vitro diagnostic industry for 20 years, developing a diversified and high-quality diagnostic testing platform [2] - The company has established various biochemical research and development platforms, including chemical methods, enzyme methods, and immunoassay techniques, and has high-level R&D capabilities in liquid blood coagulation and blood type testing [2] - Jiukang Biological's subsidiary, Maxin Biological, focuses on core technologies in pathological diagnosis and explores innovative technologies such as companion diagnostics and AI in pathology, aiming for the integrated development of six technical platforms [2]